VYGR

Voyager Therapeutics, Inc. (VYGR) | Rumor.io

Voyager Therapeutics

VYGR

Attention (50-day avg)0%

Attention rank (50-day avg)#3,237

Bullish sentiment (50-day avg)100%

Price to earnings ratio6.07

Market capitalization166.4M

Earnings per share-1.81

Dividend yield (TTM)—

Revenue (annual)40.4M

Net income (annual)-119.7M

Social

What share of all stock conversation is about VYGR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 10

Voyager Therapeutics ($VYGR) shares surge 25.1% on strong Alzheimer's disease treatment results and a cash runway into 2028.
The company's gene therapy program, VY-7523, is expected to present positive P2 results in 2H26, potentially driving further growth.
Analysts see $VYGR as a top biotech play, with heavy options flow indicating major bullish conviction and a potential 3x valuation.

Generated by AI

Sentiment

Of the messages about VYGR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	93.65% +4.18
Bearish	—	0% 0	0% 0	6.35% -4.18

Bullish· Feb 29

Voyager Therapeutics' recent earnings report was considered one of the most bullish in the industry, with many analysts impressed by the company's cash, sales, and pipeline.
The stock's strong price action, including a +15% after-hours move and a break above $12, suggests that investors are optimistic about the company's future prospects.
Voyager's solid earnings and guidance, combined with its cash runway into 2027, make it an attractive investment opportunity for those looking to capitalize on the company's growth potential.

Bearish· Apr 21

Voyager Therapeutics, Inc. ($VYGR) has seen a significant drop of 30% after being checkmated by Checkmate ($CMPI).
The company's announcement that two board members will not be nominated for re-election has led to a 28.15% decline in stock price.
The stock's sudden drop of 40% during a day suggests that bad news is lurking in the future, similar to the experience of biotech company Cel-Sci.

Generated by AI

Topics

Of the messages about VYGR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	87.16%
Analysts	—	—	100%	7%
Controversies	—	—	0%	0.78%
Earnings	—	—	0%	1.17%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	3.89%

Analysts· Oct 7

Baird upgrades Voyager Therapeutics (VYGR) to Outperform, citing a partnership with Pfizer and a price target of $9.
Compass Point initiates coverage of Voyager Therapeutics with a Buy rating and a price target of $45.
Baird sees approximately 133% upside in Voyager Therapeutics due to its partnership with Pfizer.

Announcements· Jan 5

Voyager Therapeutics, Inc. ($VYGR) has priced a public offering of 7.778M shares at $9.00 per share to raise $100M.
The company intends to use the proceeds to advance its anti-tau antibody program, SOD1 gene therapy program, tau silencing gene therapy program, and anti-amyloid gene therapy program, as well as support other preclinical development programs and working capital.
The public offering is expected to boost Voyager Therapeutics' cash reserves, allowing the company to continue its clinical development and gene therapy innovation efforts.

Technical Analysis· Oct 12

$VYGR has broken resistance at 4.96 and is expected to run, with a possible target of 5.00.
A pullback to 4.9 would be a key level to watch, with a break above it potentially leading to a move to 5.31 and 5.69.
The stock is currently consolidating around the 55 Fib EMA and above the 200 FIB EMA, with a possible pullback before its next leg.

Generated by AI

Community

Of the messages about VYGR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30%	61.65%
Newcomers	—	100%	70%	38.35%

Regulars· Jan 5

Voyager Therapeutics' CEO, Al Sandrock, is facing criticism for his credibility and decision-making after the company announced a $100m public offering.
The company plans to use the proceeds to advance its gene therapy programs, including anti-tau and anti-amyloid therapies, but existing shareholders are concerned about the impact on the share price.
Voyager Therapeutics' public offering has led to a significant drop in share price, with some analysts noting that the additional shares and warrants could be a "wet blanket" for the share price.

Newcomers· Mar 10

Newcomers are primarily focused on the potential of Voyager Therapeutics ($VYGR) as a gene therapy company, with some users believing it to be "underappreciated and undervalued".
Users are speculating about $VYGR's recent 24.18% price increase, attributing it to "heavy options flow signals major bullish conviction" and the stock's transformative year in Alzheimer's research.
The company's upcoming presentation of P2 Alzheimer Disease results in 2H26 for VY-7523 and its revenue beat estimates are seen as major catalysts for the stock's potential growth.

Generated by AI

News

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Voyager Therapeutics at wells fargo healthcare conference: key data ahead

21d agoInvesting.com

Voyager to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging ...

28d agomarkets.businessinsider.com

H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy

1mo agoInvesting.com

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX)

Detailed price information for Teleflex Inc (TFX-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about VYGR also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	BioMarin Pharmaceutical IncBMRN	0%+0
3	Denali Therapeutics Inc.DNLI	0%new
4	IGMS - IGM Biosciences, Inc.	——
5	ADVM - Adverum Biotechnologies, Inc.	——
6	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
7	Rhythm Pharmaceuticals, Inc.RYTM	0%0
8	Century Therapeutics IncIPSC	0%0
9	Solid Biosciences Inc.SLDB	0.3%new
10	SGMO - Sangamo Therapeutics, Inc.	——

Voyager Therapeutics, Inc.

Healthcare
Biotechnology

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases. The company’s current programs center on disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. Its pipeline includes tau-focused and other neuroscience candidates, while its TRACER platform is designed to support adeno-associated virus-based delivery for targeted therapies. Voyager Therapeutics works at the intersection of genetics, neurology, and drug delivery, aiming to create treatments that address conditions with limited therapeutic options. Founded in 2013 and headquartered in Lexington, Massachusetts, the company plays a specialized role in the biotechnology market through its focus on neurogenetic research and clinical-stage development.

Website

Location

75 Hayden Avenue

Lexington, MA, 02421

United States

Social

What share of all stock conversation is about VYGR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 10

Voyager Therapeutics ($VYGR) shares surge 25.1% on strong Alzheimer's disease treatment results and a cash runway into 2028.
The company's gene therapy program, VY-7523, is expected to present positive P2 results in 2H26, potentially driving further growth.
Analysts see $VYGR as a top biotech play, with heavy options flow indicating major bullish conviction and a potential 3x valuation.

Generated by AI

Sentiment

Of the messages about VYGR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	93.65% +4.18
Bearish	—	0% 0	0% 0	6.35% -4.18

Bullish· Feb 29

Voyager Therapeutics' recent earnings report was considered one of the most bullish in the industry, with many analysts impressed by the company's cash, sales, and pipeline.
The stock's strong price action, including a +15% after-hours move and a break above $12, suggests that investors are optimistic about the company's future prospects.
Voyager's solid earnings and guidance, combined with its cash runway into 2027, make it an attractive investment opportunity for those looking to capitalize on the company's growth potential.

Bearish· Apr 21

Voyager Therapeutics, Inc. ($VYGR) has seen a significant drop of 30% after being checkmated by Checkmate ($CMPI).
The company's announcement that two board members will not be nominated for re-election has led to a 28.15% decline in stock price.
The stock's sudden drop of 40% during a day suggests that bad news is lurking in the future, similar to the experience of biotech company Cel-Sci.

Generated by AI

Topics

Of the messages about VYGR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	87.16%
Analysts	—	—	100%	7%
Controversies	—	—	0%	0.78%
Earnings	—	—	0%	1.17%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	3.89%

Analysts· Oct 7

Baird upgrades Voyager Therapeutics (VYGR) to Outperform, citing a partnership with Pfizer and a price target of $9.
Compass Point initiates coverage of Voyager Therapeutics with a Buy rating and a price target of $45.
Baird sees approximately 133% upside in Voyager Therapeutics due to its partnership with Pfizer.

Announcements· Jan 5

Voyager Therapeutics, Inc. ($VYGR) has priced a public offering of 7.778M shares at $9.00 per share to raise $100M.
The company intends to use the proceeds to advance its anti-tau antibody program, SOD1 gene therapy program, tau silencing gene therapy program, and anti-amyloid gene therapy program, as well as support other preclinical development programs and working capital.
The public offering is expected to boost Voyager Therapeutics' cash reserves, allowing the company to continue its clinical development and gene therapy innovation efforts.

Technical Analysis· Oct 12

$VYGR has broken resistance at 4.96 and is expected to run, with a possible target of 5.00.
A pullback to 4.9 would be a key level to watch, with a break above it potentially leading to a move to 5.31 and 5.69.
The stock is currently consolidating around the 55 Fib EMA and above the 200 FIB EMA, with a possible pullback before its next leg.

Generated by AI

Community

Of the messages about VYGR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30%	61.65%
Newcomers	—	100%	70%	38.35%

Regulars· Jan 5

Voyager Therapeutics' CEO, Al Sandrock, is facing criticism for his credibility and decision-making after the company announced a $100m public offering.
The company plans to use the proceeds to advance its gene therapy programs, including anti-tau and anti-amyloid therapies, but existing shareholders are concerned about the impact on the share price.
Voyager Therapeutics' public offering has led to a significant drop in share price, with some analysts noting that the additional shares and warrants could be a "wet blanket" for the share price.

Newcomers· Mar 10

Newcomers are primarily focused on the potential of Voyager Therapeutics ($VYGR) as a gene therapy company, with some users believing it to be "underappreciated and undervalued".
Users are speculating about $VYGR's recent 24.18% price increase, attributing it to "heavy options flow signals major bullish conviction" and the stock's transformative year in Alzheimer's research.
The company's upcoming presentation of P2 Alzheimer Disease results in 2H26 for VY-7523 and its revenue beat estimates are seen as major catalysts for the stock's potential growth.

Generated by AI

Voyager Therapeutics

Social

Mar 10

Bullish· Feb 29

Bearish· Apr 21

Analysts· Oct 7

Announcements· Jan 5

Technical Analysis· Oct 12

Regulars· Jan 5

Newcomers· Mar 10

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Voyager Therapeutics at wells fargo healthcare conference: key data ahead

Voyager to Present at Upcoming Investor Conferences

H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX)

Also Discussed

Voyager Therapeutics, Inc.

Company Information

Location

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Voyager Therapeutics at wells fargo healthcare conference: key data ahead

Voyager to Present at Upcoming Investor Conferences

H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX)

Also Discussed

Social

Mar 10

Bullish· Feb 29

Bearish· Apr 21

Analysts· Oct 7

Announcements· Jan 5

Technical Analysis· Oct 12

Regulars· Jan 5

Newcomers· Mar 10